Three EU authorities combine forces to assess blood glucose products: results
This article was originally published in Clinica
Executive Summary
It has long been argued that resources could be saved in the overseeing of the EU medical devices market through competent authorities working more closely together. This is starting to happen with increasing frequency and results from a co-ordinated post-market surveillance operation between three regulatory authorities demonstrate how increased co-operation can give a broader and even more useful overview of what is happening in the market.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.